Neurorehabilitation Devices Market to grow at a CAGR of 14.8% during 2026 to 2035; Driven by Rising Prevalence of Neurological Disorders and Advancements in Rehabilitation Technologies

Market Research Future (MRFR) has released a comprehensive analysis of the global Neurorehabilitation Devices Market, valuing the market at USD 1.89 billion in 2025 and projecting it to grow from USD 2.17 billion in 2026, reaching USD 6.98 billion by 2035 at a compound annual growth rate (CAGR) of 14.8% during the forecast period 2026--2035.

The market is being transformed by the global increase in the incidence of neurological disorders, with more than 55 million individuals who have dementia alone, and proactive government funding for brain injury recovery tools through initiatives such as the U.S. BRAIN Initiative, which has poured more than USD 3.2 billion into neuroscience research since inception.

Market Overview

As the industry moves away from legacy manual therapy protocols and passive rehabilitation equipment toward robotic-assisted neuro therapy platforms, closed-loop brain-computer interfaces and AI-driven cognitive rehabilitation technology, neurorehabilitation devices have emerged as a strategic imperative for healthcare systems globally. The convergence of research on neural plasticity, telerehabilitation infrastructure and outcome-based payment models is fundamentally transforming the recovery of patients with stroke, Parkinson’s and spinal cord injury, creating a robust growth environment for neuro-robotic manufacturers, BCI developers and digital therapeutics companies around the world.

North America holds the largest share of about 38% of the overall market due to developed hospital infrastructure and reimbursement policies. Europe has roughly 29% of the worldwide share, with Germany and the UK leading in the use of stroke rehabilitation equipment in public health networks. The Asia-Pacific region is expected to be the fastest-growing market at an anticipated CAGR of 16.5% through 2035, supported by the widening healthcare access in China and India.

Key Market Trends & Growth Drivers

• Growing Incidence of Neurological Disorders: The World Health Organization estimates that more than 1 billion people worldwide live with neurological illnesses, and that 6.5 million people die from stroke annually. The World Alzheimer Report 2021 recorded over 55 million cases of dementia worldwide. That number is expected to rise to 78 million by 2030. The growing number of patients creates a constant and non-cyclical demand for cognitive rehabilitation technologies and recovery tools for brain damage at all levels of health care.


• Regulatory Clearances Speed Up Time-to-Market for BCI Technology: In April 2021, the FDA’s De Novo authorization for the IpsiHand Upper Extremity treatment System introduced a new regulatory path for stroke therapy devices with brain-computer interfaces. The European CE marking process has since accelerated under the MDR 2017/745 framework for brain plasticity therapy devices, and at least seven more neural interface devices have entered the FDA review queue. For qualified neurotechnology devices, these approvals reduce the average time-to-market from 5.2 years to about 3.1 years.


• Developments in Robot-Assisted Neuro Therapy: A 2023 Cochrane comprehensive analysis found that robotic exoskeletons and end-effector systems resulted in 30%-40% better upper-limb motor outcomes compared to conventional therapy. Neuro-robotics R&D attracted almost USD 1.1 billion in capital expenditure in 2024 alone, with Hocoma, Bionik Laboratories and Ekso Bionics increasing production. Robotic-assisted neurotherapy devices are moving from specialist research facilities to community rehabilitation hospitals. The installed base is growing at around 22% year-over-year in the Asia-Pacific.


• Expansion of Telerehabilitation and Remote Monitoring – The pandemic helped accelerate a permanent change to remote delivery of neurorehabilitation. A 2021 PubMed study showed telerehabilitation was effective in preserving continuity of care and reducing the global burden of disability during COVID-19 lockdowns. By 2024, over 38% of neurorehabilitation outpatient visits included some remote monitoring and cognitive rehabilitation technology platforms equipped with integrated video assessment tools now produce USD 290 million in yearly revenue.


• Demographics of Aging Population: The WHO expects that by 2050, 2.1 billion people will be aged 60+, and this will contribute to the long-term demand for cognitive rehabilitation technologies and neural plasticity therapy equipment. In 2025, Japan’s super-aging society already accounts for USD 68 million in demand for neurorehabilitation devices. MHLW rehabilitation subsidies expand the availability of brain injury recovery tools for elderly stroke survivors.

Market Segmentation Insights

By Product Type: Neuro-robotic devices hold about 35% of the Neurorehabilitation Devices Market, driven by increasing demand for robotic-assisted neuro therapy in post-stroke recovery settings. Brain-computer interfaces are the fastest-growing segment with an estimated CAGR of 18.2% and are driven by regulatory clearances and increasing clinical evidence for neural plasticity therapy devices. Non-invasive stimulators are projected to generate approximately USD 420 million in revenue by 2025, fueled by outpatient adoption and enhanced insurance coverage. Wearable devices are expected to grow at a CAGR of 16.3% through 2035, reflecting growth in home-use and outpatient rehabilitation.

By Application: Brain stroke is driving demand, with 6.5 million deaths a year worldwide and a crucial need for stroke rehabilitation devices in the first 90 days after the event. High-growth indications including Parkinson’s disease and multiple sclerosis have disease-modifying medicines that extend patient survival and lengthen the rehabilitation window. The main categories are completed by spinal cord damage and cerebral palsy, with schizophrenia being a new use for cognitive rehabilitation technology.

By End User: Hospitals and Clinics hold the greatest end-user share in the Neurorehabilitation Devices Market at around 52%, fueled by capital equipment procurement cycles and access to expert staffing. Specialized brain injury recovery tools are emerging as a focal point in dementia and TBI treatment protocols, with cognitive care facilities projected to have a CAGR of 16.1%. Home care and research institutes are projected to produce USD 215 million in 2025 as direct-to-patient device approvals and clinical trial demand grow.

By Setting of Care: The capital intensity of neuro-robotic systems and the need for expert therapist supervision anchor demand in inpatient rehabilitation centers. Outpatient clinics are quickly developing with telerehabilitation platforms allowing remote professional supervision. Home-based settings are the fastest-increasing care setting. Compact wearable neural stimulators and gamified brain injury recovery tools for unsupervised home use are expected to reach over USD 850 million by 2032.

Regional Landscape

North America -- Technology Adoption Leader

North America dominates the worldwide neurorehabilitation devices market with a share of around 38%. The region is experiencing growth fuelled by advanced hospital infrastructure, favorable reimbursement frameworks and the NIH’s BRAIN Initiative dedicating USD 690 million in fiscal year 2024 alone for neurotechnology development. The U.S. has the region’s largest stake at 78% as a result of CMS’s extension of Medicare CPT codes for cognitive rehabilitation technologies and the addition of new payment codes for brain-computer interface therapy sessions beginning in January 2025. The other key contributor is Canada, with provincial stroke rehabilitation equipment funding leading to a CAGR of 13.8%. Mexico: A growth market for private hospital chain investment to reach USD 32 million by 2025.

Europe -- Emerging Market Dynamics

Europe represents over 29% of the global market, supported by public stroke rehabilitation programs, MDR compliance and the European Research Council’s involvement in brain plasticity research. Germany is the regional leader with 24% of the regional share, supported by a well-established DRG reimbursement mechanism that expressly codes for robotic-assisted neuro treatment and non-invasive stimulation sessions. The United Kingdom is next with a CAGR of 14.1%, owing to the NHS Long Term Plan that has allocated GBP 2.3 billion for stroke care improvements till 2028. Major markets are France, Italy and Spain, with Nordic nations leading the way in digital health integration mandates. “Key players like Hocoma and MindMaze are driving innovation, and competition is increasing with a growing base of BCI specialists.

Asia-Pacific -- Rapid Growth and Innovation

Asia Pacific is the fastest-growing region in the Neurorehabilitation Devices Market with a CAGR of 16.5% over the period of 2035. Growth is driven by infrastructure build-out, aging demography and increasing access to healthcare, particularly in China and India. China accounts for 36% of the regional share, with the State Council rehabilitation services plan seeking to create dedicated neurorehabilitation facilities in all prefecture-level cities by 2030 (more than 330 new facility installations). The Neurorehabilitation Devices Market is led by Ayushman Bharat infrastructure expansion driving the fastest country-level pace, with India in second place with an 18.4% CAGR. Japan and South Korea drive demand for rehabilitation due to super-aging society and expansion of national health insurance coverage. Japan generates USD 68 million in 2025.

Middle East and Africa: Untapped Market Potential

The Middle East and Africa area is a smaller but fast-growing piece of the whole, spurred by investment in healthcare infrastructure and the rising need for brain injury recovery technologies. Regional leader Saudi Arabia holds a 31% share, with Vision 2030’s diversification in healthcare driving large investments in advanced rehabilitation infrastructure, such as dedicated neurorehabilitation centers in Riyadh and Jeddah with robotic-assisted neurotherapy systems. Premium hospital networks are growing at a 14.9% CAGR as the UAE capitalises on its medical-tourism position. Rehabilitation centers in South Africa, established as public-private partnerships, and Egypt’s national program for controlling neurological diseases are starting to make devices for neural plasticity therapy available to larger populations

Competitive Landscape

The Neurorehabilitation Devices Market is moderately concentrated, with the top five players accounting for an estimated 42-48% of combined revenue. Key players include Hocoma (DIH Group), Ekso Bionics, Bionik Laboratories, Medtronic, Abbott Laboratories, BrainCo, Nuvectra Corporation, MindMaze, Neurolutions, and Nexstim. Recent major developments include:

• In March 2025, Abbott Laboratories secured FDA approval for its next-generation Proclaim XR closed-loop spinal cord stimulator with AI-adaptive algorithms, pushing forward non-pharmacological pain relief technology and neural plasticity therapy device capabilities.


• February 2022 – MindMaze secured USD 105 million in a funding round to accelerate global commercial expansion, enhance ongoing R&D and optimize the clinical development pipeline of its industry-leading digital therapeutic solutions for neurological diseases.


• Alliance Equiphoria sponsored a clinical trial in April 2022, “Neurorehabilitation Through Hippotherapy of a Brain Stroke (HippoPostCVA),” to evaluate the effect of a hippotherapy program on the functional and global evolution of post-stroke patients in outpatient rehabilitation.


• In 2024, Ekso Bionics expanded its manufacturing capacity to meet the growing demand for its EksoNR exoskeleton platform, with the Asia-Pacific region witnessing an installed-base growth of approximately 22% year-on-year.


• Neurolutions got FDA De Novo clearance in April 2021 for the IpsiHand System, the first brain-computer interface for stroke rehabilitation equipment, establishing a new regulatory avenue for BCI-based neural plasticity therapy products.


• As part of its InMotion robotic systems portfolio expansion in 2024, Bionik Laboratories will offer AI-powered upper-extremity brain injury recovery solutions to community rehab hospitals and outpatient clinics.

Future Outlook

Further advances in AI-powered personalized rehabilitation protocols with closed-loop adaptive therapy, expanded home-use neurorehabilitation devices and platform economics, and deepening penetration into emerging markets across Asia-Pacific, the Middle East and Africa will reshape the Neurorehabilitation Devices Market by 2035. Outsized growth will go to organizations focused on AI and closed-loop adaptive therapy systems, device-as-a-service and outcome-based payment models, and global health justice via frugal innovation.

The MRFR report identifies key growth opportunities such as the integration of AI-powered personalized rehabilitation protocols that accelerate motor recovery timelines by 25% compared to standardized programs, the development of home-use neurorehabilitation devices projected to exceed USD 850 million by 2032, and the expansion of customized neurorehabilitation in high-growth emerging markets where government neuroscience funding programs and rehabilitation infrastructure development ensure baseline demand for stroke rehabilitation equipment and neural plasticity therapy devices.